iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week
Rhea-AI Summary
Insight Molecular Diagnostics (Nasdaq: IMDX) will report Q3 2025 financial results after market close on November 10, 2025. The company will host a live Zoom webinar and Q&A at 2:00 PM PT / 5:00 PM ET the same day; registration and an archived replay will be available on the company’s investor relations site.
Separately, CEO Josh Riggs will attend the Stephens NASH25 Conference in Nashville on November 19, 2025 (event runs November 18–20); investors can request one‑on‑one meetings via their Stephens sales representative.
Positive
- None.
Negative
- None.
News Market Reaction 2 Alerts
On the day this news was published, IMDX gained 1.83%, reflecting a mild positive market reaction. Argus tracked a trough of -12.3% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $175M at that time.
Data tracked by StockTitan Argus on the day of publication.
NASHVILLE, Tenn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report third quarter 2025 financial results after the market closes on Monday, November 10, 2025. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day.
The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDX Q3 2025 Earnings Webinar.
An archived replay will be available after the call concludes on iMDX’s investor relations website at https://investors.imdxinc.com/.
Stephens NASH25 Conference
Separately, on November 19th, Chief Executive Officer Josh Riggs will attend the Stephens NASH25 Conference, taking place from November 18-20, 2025.
Investors wishing to book one-on-one meetings with management are encouraged to reach out to their Stephens sales representative.
Event: Stephens NASH25 Conference
Dates: November 19, 2025
Location: Nashville, TN
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc., or iMDx, formerly Oncocyte Corp. (OCX), is a pioneering precision diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. iMDx utilizes a well-established proprietary approach to quantify dd-cfDNA, which is a widely used molecular biomarker of transplant rejection.
iMDx™, GraftAssure™, GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, and VitaGraft™ are trademarks of Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics (Nasdaq: IMDX) moved its headquarters from Irvine, Calif., to Nashville, Tenn., in June 2025. The company’s new NASDAQ symbol became effective June 18. Investors may visit https://investors.imdxinc.com/ for more information.
Investor Contact:
Doug Farrell
LifeSci Advisors LLC
dfarrell@lifesciadvisors.com
FAQ
When will Insight Molecular Diagnostics (IMDX) release Q3 2025 results?
What time is the IMDX Q3 2025 earnings webinar and how can I join?
Will there be a replay of the IMDX Q3 2025 earnings call?
Is IMDX management attending the Stephens NASH25 Conference?
How can investors schedule one‑on‑one meetings with IMDX at the NASH25 Conference?
